Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Chimerix, Inc. - Common Stock (NQ:CMRX)

8.540 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Chimerix, Inc. - Common Stock

< Previous 1 2 3 Next >
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
Via Investor Brand Network
Topics Artificial Intelligence
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
From Chimerix, Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, CMRX, WBA, ML on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
From Brodsky & Smith LLC
Via GlobeNewswire
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
From Chimerix, Inc.; Jazz Pharmaceuticals plc
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Speak Today at The White House Cancer Moonshot Forum
Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development 
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility 
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.